^Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
December 15, 2023
sabcomeline, memric, selective, receptor, partial, agonist, that, under, development, treatment, alzheimer, disease, made, phase, clinical, trials, before, being, discontinued, poor, results, clinical, dataatc, codenonelegal, statuslegal, statusnever, marketed. Sabcomeline Memric SB 202 026 is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer s disease 1 It made it to phase III clinical trials before being discontinued due to poor results SabcomelineClinical dataATC codeNoneLegal statusLegal statusNever marketedIdentifiersIUPAC name 3Z 3R N methoxy 1 azabicyclo 2 2 2 octane 3 carboximidoyl cyanideCAS Number159912 53 5 YHCl 159912 58 0 YPubChem CID9577995IUPHAR BPS306ChemSpider7852359UNIIP8P92V596CHCl A24BK93DRR YChEMBLChEMBL134641Chemical and physical dataFormulaC 10H 15N 3OMolar mass193 250 g mol 13D model JSmol Interactive imageSMILES C2CC1CCN2CC1 C C N N OCSee also editAlvameline Milameline Tazomeline XanomelineReferences edit Loudon JM Bromidge SM Brown F et al December 1997 SB 202026 a novel muscarinic partial agonist with functional selectivity for M1 receptors The Journal of Pharmacology and Experimental Therapeutics 283 3 1059 68 PMID 9399977 Retrieved from https en wikipedia org w index php title Sabcomeline amp oldid 1149775215, wikipedia, wiki, book, books, library,
